Max Herrmann
Analyst-Equity chez Stifel Nicolaus Europe Ltd.
Profil
Max Herrmann is an Analyst at Stifel Nicolaus Europe Ltd.
since 2015.
He previously worked as Managing Director & Head-European Pharmaceutical at ING Groep NV, Director at Regenerative Medicine Assets Ltd., Director at Intercytex Ltd., Director at Axordia Ltd., Financial Controller at Onyx Pharmaceuticals, Inc., and Research Analyst at ING Bank NV (United Kingdom).
He was also the Chief Financial Officer & Secretary at Silence Therapeutics Plc from 2010 to 2012 and an Analyst at Oriel Securities Ltd.
from 2013 to 2015.
Mr. Herrmann obtained an undergraduate degree from the University of Kent.
Postes actifs de Max Herrmann
| Sociétés | Poste | Début |
|---|---|---|
Stifel Nicolaus Europe Ltd.
 Stifel Nicolaus Europe Ltd. Investment Banks/BrokersFinance Stifel Nicolaus Europe Ltd. (SNEL) is a brokerage firm headquartered in London, UK. The firm was founded in 1999 and do-business-as Keefe, Bruyette & Woods Ltd. (KBW). They are a subsidiary of Stifel Europe Holdings Ltd., ultimately owned by Stifel Financial Corp. (NYSE: SF) in the US. SNEL provides Pan-European equity research and sales and trading products for their institutional clients. | Analyst-Equity | 03/02/2015 |
Anciens postes connus de Max Herrmann
| Sociétés | Poste | Fin |
|---|---|---|
| Oriel Securities Ltd. | Analyst-Equity | 01/02/2015 |
Axordia Ltd.
 Axordia Ltd. Miscellaneous Commercial ServicesCommercial Services Axordia Ltd. develops human embryonic stem cell applications. Its applications include dry AMD, next generation stents, and GMP-compliant HESC lines. The company was founded by Peter W. Andrews and Harry Moore in 2001 and is headquartered in Sheffield, UK. | Directeur/Membre du Conseil | 18/04/2013 |
| SILENCE THERAPEUTICS PLC | Directeur Financier/CFO | 02/08/2012 |
| ING Bank NV (United Kingdom) | Analyst-Equity | 01/06/2007 |
Regenerative Medicine Assets Ltd.
 Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Directeur/Membre du Conseil | - |
Formation de Max Herrmann
| University of Kent | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ING GROEP N.V. | Finance |
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Entreprise privées | 7 |
|---|---|
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
| ING Bank NV (United Kingdom) | Finance |
Regenerative Medicine Assets Ltd.
Regenerative Medicine Assets Ltd. Pharmaceuticals: MajorHealth Technology Regenerative Medicine Assets Ltd. engaged in the healthcare business. The company was founded by Paul Kemp in 2000 and was headquartered in Bristol, the United Kingdom. | Health Technology |
Intercytex Ltd.
 Intercytex Ltd. Pharmaceuticals: MajorHealth Technology The company is developing cell-based treatments for skin and hair regeneration. Its TrichoCyte product candidate is injected just beneath the scalp to encourage new hair follicles to form. Another product candidate, ProtoDerm, could treat diabetic ulcers and other chronic dermal wounds. | Health Technology |
| Oriel Securities Ltd. | Finance |
Axordia Ltd.
Axordia Ltd. Miscellaneous Commercial ServicesCommercial Services Axordia Ltd. develops human embryonic stem cell applications. Its applications include dry AMD, next generation stents, and GMP-compliant HESC lines. The company was founded by Peter W. Andrews and Harry Moore in 2001 and is headquartered in Sheffield, UK. | Commercial Services |
Stifel Nicolaus Europe Ltd.
Stifel Nicolaus Europe Ltd. Investment Banks/BrokersFinance Stifel Nicolaus Europe Ltd. (SNEL) is a brokerage firm headquartered in London, UK. The firm was founded in 1999 and do-business-as Keefe, Bruyette & Woods Ltd. (KBW). They are a subsidiary of Stifel Europe Holdings Ltd., ultimately owned by Stifel Financial Corp. (NYSE: SF) in the US. SNEL provides Pan-European equity research and sales and trading products for their institutional clients. | Finance |